CRDF · Cardiff Oncology, Inc.

Cardiff Oncology Inc Is A Clinical-Stage Biotechnology Company Advancing Cancer Treatments Focused On Plk1 Inhibition, A Validated Oncology Target With Practice-Changing Potential. Its Main Asset, Onvansertib, Is A Specific, Oral Plk1 Inhibitor Currently Being Evaluated In A Phase 2 Trial For First-Line Treatment Of Ras-Mutated Metastatic Colorectal Cancer (Mcrc), Addressing A Large, Underserved Patient Population With High Unmet Need. Onvansertib Is Also Under Investigation In Other Plk1-Driven Cancers Through Ongoing Investigator-Initiated Trials And Has Shown Robust Single Agent Clinical Activity In Hard-To-Treat Tumors. By Targeting Tumor Vulnerabilities, To Overcome Treatment Resistance And Deliver Improved Clinical Outcomes For Patients.